Q1 Sales & Earnings: An Opportunity For Clarity In An Uncertain Time
Executive Summary
Johnson & Johnson is the first big pharmaceutical company to report first quarter financial results, and investors across the industry are interested in hearing how the COVID-19 pandemic is impacting the sector's fundamental business dynamics.
You may also be interested in...
AbbVie Presents Optimistic Take For 2020, Expects Quick Recovery For Botox Aesthetic
AbbVie made only a slight adjustment to its earnings-per-share guidance despite expected Q2 downturn due to the pandemic. It sees Allergan’s aesthetic business as bouncing back quickly.
Sage Makes Deep Cuts, Axing 53% Of The Workforce, As It Reins In Zulresso
The company will cut 340 positions, primarily affecting Zulresso commercial operations, to save $170m, after announcing it will need to run new trials to support the regulatory plan for zuranolone.
Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.